<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795899</url>
  </required_header>
  <id_info>
    <org_study_id>TECHNO</org_study_id>
    <nct_id>NCT00795899</nct_id>
  </id_info>
  <brief_title>Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)</brief_title>
  <official_title>Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Breast Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present clinical trial will investigate the safety and efficacy of a sequential&#xD;
      preoperative therapy with Epirubicin/Cyclophosphamide in combination with&#xD;
      Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2&#xD;
      overexpression primary breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the rate of cardiac (serious) events NYHA III/IV-and pathological complete remission after study therapy.</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess: the rate of breast conserving surgery, the clinical response rates, the histopathological lymph node status after preoperative therapy, the disease-free and overall survival.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the quality of life.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab</intervention_name>
    <description>Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d&#xD;
Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary carcinoma of the breast, confirmed histologically by core biopsy (at least 3&#xD;
             core biopsy samples)&#xD;
&#xD;
          2. Tumor lesion of the breast with a palpable or a imagistic size ≥ 2 cm or inflammatory&#xD;
             breast cancer&#xD;
&#xD;
          3. Known HER-2 status detected on core biopsy. HER-2 over expression is defined as DAKO&#xD;
             HercepTest (3+) or DAKO HercepTest (2+) and FISH (+)&#xD;
             (fluorescence-in-situ-hybridisation).&#xD;
&#xD;
          4. No distant metastatic disease, confirmed by chest x-ray, abdominal sonography and bone&#xD;
             scan.&#xD;
&#xD;
          5. Female patients&#xD;
&#xD;
          6. Age ≥ 18 and ≤ 65 years&#xD;
&#xD;
          7. ECOG &lt; 2/WHO 0-1&#xD;
&#xD;
          8. Laboratory requirements GOT and Bilirubin &lt; 1.5x UNL Leukocytes &gt;= 3 G/l Neutrophile &gt;&#xD;
             1 G/l Thrombocytes &gt; 100 G/l Creatinine (Serum) &lt; 2.0 mg/dl.&#xD;
&#xD;
          9. Normal cardiac function, confirmed by cardiologist&#xD;
&#xD;
         10. No active hepatitis&#xD;
&#xD;
         11. Written informed consent for all study procedures&#xD;
&#xD;
         12. Patients must be available and compliant for treatment and follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multicentricity in various quadrants (contact the study office)&#xD;
&#xD;
          2. CNS-metastases&#xD;
&#xD;
          3. Secondary malignancy, excluding basalioma of the skin or carcinoma in situ of the&#xD;
             cervix that has received curative therapy&#xD;
&#xD;
          4. Patients with relevant hemodynamic cardial diseases&#xD;
&#xD;
          5. Patients with a left ventricular ejection fraction (LVEF) under the normal limit of&#xD;
             the institution, confirmed by echocardiography or MUGA-Scan.&#xD;
&#xD;
          6. Uncontrolled, severe comorbidities&#xD;
&#xD;
          7. Patients with severe respiratory diseases and severe dyspnea and / or which need&#xD;
             supportive oxygen&#xD;
&#xD;
          8. Previous anti-HER2-therapy&#xD;
&#xD;
          9. Patients receiving immunosuppressant therapy&#xD;
&#xD;
         10. Known allergy to medication containing cremophor&#xD;
&#xD;
         11. Hb &lt;10 g/dL, Neutrophile &lt;1.5 x109/L, Thrombocytes &lt;100 x109/L.&#xD;
&#xD;
         12. Total-Serum-Bilirubin &gt;1.5 x ULN (upper limit of normal) (except in patients with&#xD;
             confirmed and documented Gilbert-Lereboullet-syndrome), ALT or AST &gt;2.5 x ULN (&gt;5 x&#xD;
             ULN by liver metastases), Alkaline Phosphatase &gt;2.5 x ULN (&gt;4 x ULN by liver or bone&#xD;
             metastases), Serumcreatinine &gt; 2 x ULN&#xD;
&#xD;
         13. Pregnancy, nursing (a negative pregnancy test must be documented, and safe&#xD;
             anticontraceptive measures during pre- and postoperative treatment must be&#xD;
             implemented)&#xD;
&#xD;
         14. Lack of signed informed consent after informing the patient&#xD;
&#xD;
         15. Lack of willingness to keep and disclose personal medical data as part of the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Untch, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGO Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Maximillian University Munich, Department of Gynecology and Obstetrics</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>August 15, 2011</last_update_submitted>
  <last_update_submitted_qc>August 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Udo Pfeil</name_title>
    <organization>GBG Forschungs GmbH</organization>
  </responsible_party>
  <keyword>Safety and efficacy of experimental treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

